Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other financing activities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Other financing activities for 7 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to $600000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.9 million through Dec 2025, down 552.03% year-over-year, with the annual reading at $2.2 million for FY2025, N/A changed from the prior year.
  • Other financing activities hit $600000.0 in Q4 2025 for BridgeBio Pharma, up from -$10.5 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $6.8 million in Q1 2021 to a low of -$10.5 million in Q3 2025.
  • Historically, Other financing activities has averaged $699166.7 across 5 years, with a median of $901500.0 in 2023.
  • Biggest five-year swings in Other financing activities: surged 2048.21% in 2023 and later plummeted 1048500.0% in 2025.
  • Year by year, Other financing activities stood at $3.7 million in 2021, then plummeted by 130.24% to -$1.1 million in 2022, then grew by 28.48% to -$801000.0 in 2023, then surged by 100.12% to $1000.0 in 2024, then soared by 59900.0% to $600000.0 in 2025.
  • Business Quant data shows Other financing activities for BBIO at $600000.0 in Q4 2025, -$10.5 million in Q3 2025, and $2.0 million in Q2 2025.